ArticleMedical care2009
Racial disparities in treatment preferences for rheumatoid arthritis.
Article in Medical care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.Arthritis research & therapy · 2022Pooled it
- Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review.JAMA network open · 2019Pooled it
- A Systematic Review of Race/Ethnicity and Parental Treatment Decision-Making.Clinical pediatrics · 2018Pooled it
- Variability in Affect and Willingness to Take Medication.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Trial
- African American patients with gout: efficacy and safety of febuxostat vs allopurinol.BMC musculoskeletal disorders · 2012Trial
- Real-world treatment courses after anti-TNF de-escalation in older adults with rheumatoid arthritis: a medicare cohort study.BMC rheumatology · 2026Article
- Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.Rheumatology and therapy · 2024Article
- Initiation of Disease-Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late-Onset Rheumatoid Arthritis.ACR open rheumatology · 2023Article
- Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment.BMC rheumatology · 2023Article
- Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treat-to-Target Rates.ACR open rheumatology · 2022Article
- Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis.Clinical rheumatology · 2022Article
- Health disparities in rheumatoid arthritis.Therapeutic advances in musculoskeletal disease · 2022Review
- How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran.Applied health economics and health policy · 2021Article
- Observational
- Antecedents of Vaccine Hesitancy in WEIRD and East Asian Contexts.Frontiers in psychology · 2021Review
- Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention.Pediatric rheumatology online journal · 2020Article
- Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives.Arthritis care & research · 2020Article
- Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis.Arthritis care & research · 2019Article
- Understanding the Factors That Influence Risk Tolerance Among Minority Women: A Qualitative Study.Arthritis care & research · 2018Article
- Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.Rheumatology and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundData suggest that differences in patient preferences may account for racial disparities in the use of medical interventions. Racial disparities have also been noted in outcomes and the delivery of healthcare services in chronic disease. Whether treatment preferences in chronic disease differ by race is not known.
methodsWe elicited treatment preferences for aggressive therapy in patients with rheumatoid arthritis who identified themselves as being black or white.
resultsOne hundred fifty consecutive eligible patients were invited to participate. Of these, 136 subjects completed the interview. In unadjusted analysis, 51% of white participants preferred aggressive therapy compared with 16% of blacks (P < 0.0001). Subjects who were married and reported having at least some college education had stronger preferences for aggressive therapy compared with their respective counterparts. After adjusting for covariates, race remained the strongest predictor of aggressive therapy examined in this study [adjusted odds ratio (95% confidence interval) = 11.2 (1.9-64.9)].
conclusionsIn this study, fewer black patients preferred aggressive treatment compared with white patients with similar disease severity. These results have important clinical implications because use of aggressive treatment improves both short- and long-term outcomes in rheumatoid arthritis. Efforts to improve patient education and physician communication should be made to ensure that all patients have an accurate understanding of the benefits, as well as risks, associated with the best available treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.